Skip to main content
Publications
Mordin M , Bhogal P , Warttig S , Gildea L , Long J , D'Souza V , Kinderas M , Ling C , Hartley L . HTA requirements for medical technologies in Canada . Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA.
Mordin M , Bhogal P , Warttig S , Gildea L , Long J , D'Souza V , Kinderas M , Ling C , Hartley L . What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA.
Halsby K, Gildea L , Colosia A , Madhava H, Erber W, Angulo F, Pilz A, Schley K, Moisi J, Sellner J. The clinical spectrum of TBE infections in adult and paediatric populations in Europe: a systematic review . Poster presented at the International Symposium on Tick-Borne Pathogens and Disease (ITPD) 2023; October 24, 2023. Vienna, Austria.
Fernandez M, Bell TJ, Khan S , Tumminello B, Bektas M , Heyes CE , Oton AB. Burden of illness of desmoid tumors . Poster presented at the 2022 CTOS Annual Meeting; November 16, 2022. Vancouver, Canada. Previously presented at the 2022 Desmond Tumor Research Foundation (DTRF) Annual Meeting.
Hartry A, Menne H, Wronski S, Paulson R, Callahan L, Potashman M, Lee D, Wunderlich G, Hoffman D, Wieberg D, Kremer I, Hauber B, DiBenedetti D . Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's Disease . Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 29, 2020.
Njue A , Margulis AV , Lyall M, Nuabor W , Marks M, Russell K, Sinha A. Congenital cytomegalovirus: what are the rates of maternal screening, diagnostic amniocentesis, and elective termination? Poster presented at the ID Week 2019; October 4, 2019. Washington, DC.
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides better relief from psoriasis impact on personal relationships than etanercept . Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Gottlieb AB, Pariser D, Tsai TF, Pinter A, Zhou Y, Gilloteau I, Mordin M , Davenport E , Guana A, Reich K. Secukinumab provides greater 52-week sustained relief in dermatology-specific quality-of-life impact than ustekinumab . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Puig L, Sofen H, Augustin M, Abramovits W, Kingo K, Gilloteau I, Zhao Y, Mordin M , Williams N, Guana A, Korman N. Secukinumab provides greater 52-week improvements in patient-reported outcomes versus ustekinumab in patients with moderate to severe psoriasis . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.